We aimed to establish a panel of MHC-peptide multimers suitable as a positive control in the detection of HLA A*0201 restricted antigen specific T cells (ASTC) by flow cytometry. MHC Dextramers were loaded with HLA A*0201 binding peptides from viral antigens and melanoma targets identified from a literature search and in silico prediction. Peripheral blood mononuclear cells (PBMC) from healthy donors were analysed with the MHC Dextramers using flow cytometry. The best performing epitopes were tested on PBMC from patients undergoing testing for Mycobacterium tuberculosis infection to assess the coverage of this epitope panel. Of 21 candidate epitopes, ASTC could be detected against 12 (57Á1%) in at least one of 18 healthy blood donors. Reactivity to two or more epitopes was seen in 17 of the 18 donors (94Á4%). We selected the six best-performing epitopes and demonstrated a positive response in 42 (97Á7%) of 43 patient samples (healthy, latent and active M. tuberculosis infection). The selected panel of six antigenic epitopes sufficed as a positive control in the detection of ASTC in HLA A*0201. Performance was robust in different stages of latent and active M. tuberculosis infection, indicating reliability also during infection.
Introduction
Cytotoxic CD8 + T lymphocytes (CTL) are a cornerstone in the immunological response against viral infections, [1] [2] [3] cancer cells 4, 5 and certain intracellular protozoal, parasitic 6 and bacterial 7, 8 infections. Interaction between a naive CTL and an appropriately activated antigen-presenting cell leads to activation and clonal expansion of CTL, with subsequent differentiation and formation of both primary effector cells and long-lived memory T cells. 9 This allows for rapid response to future encounters with the same antigen. Activated CTL circulate the organism and exhibit their cytotoxic function through interaction between the T-cell receptor and Class I MHC molecules expressed on all nucleated cells.
Detection of antigen-specific T cells (ASTC) ex vivo is of great importance in studies of cancer immunology, 5 immune protection in infectious diseases 10, 11 and in vaccine efficacy. 12, 13 ASTC can be measured directly using MHC multimers, 14 which consist of multiple MHC molecules and fluorochrome labels detectable by flow cytometry. Interaction between a single MHC molecule and its cognate T-cell receptor is weak; but combining multiple MHC molecules into a multimer increases the overall avidity sufficiently to make a stable interaction, suitable for labelling the ASTC. 15 The first multimers introduced were tetramers, consisting of four MHC molecules attached to a streptavidin core through a biotinylation of the MHC-peptide complex. The newer MHC Dextramers are constructed by attaching multiple MHC monomers to a Dextran backbone labelled with multiple fluorochrome molecules. This results in a higher signal from each bound MHC-Dextramer molecule, significantly increasing the signal-to-noise ratio compared with MHC tetramers. 16 Detecting ASTC can be challenging, because of the low frequency of circulating ASTC recognizing a specific epitope. A reliable assay control for use of MHC multimers in flow cytometry-based assays does not exist. 17 Although the human CTL repertoire shows great variations, also within HLA genotypes, certain epitopes, primarily from common viruses, are likely to be recognized in most individuals, and may serve as positive controls in flow cytometric analyses ª 2017 John Wiley & Sons Ltd, Immunology, 152, 298-307 of ASTC. To control assay performance for detection of these rare cells, we investigated a number of virus-and melanoma-related epitopes for reactivity with ASTC, and constructed a panel of MHC Dextramers displaying epitopes with the highest possible coverage in HLA A*0201-positive subjects. The panel was subsequently tested in peripheral blood mononuclear cells (PBMC) from healthy controls, as well as in patients with latent and active tuberculosis (TB). This was done to test assay performance in health and during different stages of chronic infection.
Methods
Previously described peptide epitopes with broad coverage for detection of ASTC in human blood were identified using PubMed to search the Medline library for publications reporting such epitopes. In addition, epitopes from pathogens included in commonly applied human vaccinations, such as tetanus and measles, were included in the analysis. Peptides/epitopes presented by the MHC class I A*0201 allele were predicted using the online in silico prediction tool NETMHC 4Á0 (Faculty of Health Sciences, University of Copenhagen). 18, 19 Recombinant MHC class I protein purified from Escherichia coli (Immudex ApS, Copenhagen, Denmark) was refolded with the selected peptides (TAG Copenhagen, Denmark or JPT, Germany), forming MHC-peptide momoners. The monomers were multimerized to the dextran backbone labelled with either phycoerythrin (PE), allophycocyanin (APC) or fluorescein isothiocyanate (FITC) (Immudex ApS) as appropriate.
In the initial screening of MHC Dextramers to establish the epitope panel, we stained PBMC from each donor with three different MHC Dextramers simultaneously; each MHC Dextramer was labelled with a specific fluorochrome (PE, APC or FITC). For validation of the selected epitope panel, we produced MHC Dextramers labelled with two different flourochromes (PE and APC) for each epitope. PBMC were double-stained with the PE-and APC-labelled MHC Dextramers for increased specificity.
Patient samples
From 18 anonymous, healthy blood donors, cell material in the form of buffy coats derived from whole blood was obtained from the blood bank at Rigshospitalet, Capital Region, Denmark (Cohort 1). From buffy coats, PBMC were isolated on Ficoll-Paque using a standard procedure. Purified PBMC were cryopreserved in liquid nitrogen until analysis.
For validation of selected epitopes, fresh heparinized blood was collected from patients undergoing testing for active or latent Mycobacterium tuberculosis infection at the Department of Respiratory Diseases and Allergy or the Department of Infectious Diseases at Aarhus University Hospital, Aarhus, Denmark (Cohort 2). From the heparinized blood, PBMC were isolated as described above and cryopreserved in liquid nitrogen until analysis. The samples were stored in a biobank established during a project regarding detection of M. tuberculosis-specific CTL, and was approved by the Central Denmark Region Committee on Health Research Ethics as well as by the Danish Data Protection Agency. In addition, samples from 10 healthy blood bank donors (Rigshospitalet, Capital Region, Denmark) were included in Cohort 2.
For patients in Cohort 2, we included data on age, gender and result of the interferon-c release-assay (IGRA) Tspot.TB (Oxford Immunotec, Abingdon, UK), which is an ELISpot assay measuring response to the M. tuberculosis antigens ESAT-6 and CFP-10.
All samples were HLA typed (Cohort 1: IMGM Laboratories GmbH, Martinsried, Germany; Cohort 2: Histogenetics, Ossining, NY).
MHC-Dextramer staining
The PBMC were thawed at room temperature immediately before staining, and cell suspension transferred to PBS with 5% fetal calf serum (FCS) when almost thawed. The cell suspension was centrifuged at 300 g for 10 min. The cell pellet was resuspended in PBS with 5% FCS and washed twice. A 100-ll cell suspension was stained with 5 ll MHC-Dextramer reagent and incubated in the dark at room temperature for 10 min. For the validation experiments (Cohort 2), a pool of MHC Dextramers was used. The pool was generated by mixing 5 ll of each of the selected MHC Dextramer reagents in a tube containing 5 ll 10 mM D-Biotin. Before Dextramer staining, cells were stained with Cascade Yellow fixable viability stain, according to the manufacturer's instructions (ThermoFischer Scientific, Waltham, MA), to exclude dead cells.
After incubation with Dextramers, titrated amounts of antibodies [anti-CD3/Peridinin chlorophyll protein (PerCP) (UCHT1; ThermoScientific), anti-CD8/Pacific Blue (PB) (SK1, BioLegend, San Diego, CA), or anti-CD4/PerCP) as appropriate] were added, and cells were incubated in the dark at room temperature for 20 min.
Subsequently, cells were washed twice with 2-3 ml PBS with 5% FCS and centrifuged at 300 g for 5 min. Finally, cells were resuspended in 400 ll PBS with 5% FCS, and acquired in a flow cytometer (CyAn ADP, DakoCytomation).
Flow cytometry
Every day, anti CD3 or CD4 control stainings were prepared for each fluorochrome used, for compensation purposes. The stained cell samples were acquired on a CyAn ADP flow cytometer (Dako, Glostrup, Denmark) within 2 hr after preparation. Identification of the MHC-Dextramer-positive cell population was obtained by serial gating of the flow data. The lymphocyte population was gated using side scatter (SSC) versus forward scatter and was 'purified' by excluding doublets ( The gating strategy is illustrated in Fig. 1 . In Cohort 1, a positive response was defined by presence of an MHCDextramer-positive cell population, clearly different from the MHC-Dextramer-negative cells regardless of absolute positive cell count, in order not to exclude low-frequency responses at this stage. In Cohort 2, a positive result was defined by the Dextramer-positive events constituting at least 0Á1% of all CD3 + CD8 + lymphocytes.
Data analysis
Flow cytometry data were analysed using FLOWJO, version 10 (FlowJo LLC, Ashland, OR). Statistical analyses were performed using STATA, version 14 (StataCorp, College Station, TX). Percentages of MHC-Dextramer-positive cells were summarized as geometric means and compared by Student's t-test on log-transformed data. Additionally, data were presented using box-whisker plots.
Results

Epitope selection
By a literature search and in silico prediction, we identified 21 HLA-A*0201 restricted epitopes, derived from six widespread human viruses [cytomegalovirus (CMV), EpsteinBarr virus (EBV), influenza virus, measles virus, human papilloma virus (HPV) and herpex simplex virus (HSV)], as well as an endogenous antigenic target, expressed by melanocytes as well as melanoma-cells (Table 1) .
Establishing an epitope panel
We tested the candidate epitopes on PBMC from 18 healthy blood donors (Cohort 1) positive for HLA A*0201. For 12 (57Á1%) of the epitopes, ASTC were detected in at least one of the 18 donors ( Table 1 ). The best coverage was achieved with the EBV epitope GLCTLVAML (78% of donors). Reactivity to two or more of these epitopes was seen in 17 of the 18 donors (94Á4%); one donor did not react to any of the epitopes. The highest coverage with the lowest number of epitopes was obtained by combining the two epitopes GLCTLVAML (EBV) and GILGFVFTL (influenza virus), yielding a coverage of 17/18 (94Á4%) or 100% if only counting donors in whom any ASTC were detected.
The six best performing epitopes in combination yielded a response against two or more epitopes in 15 donors (83Á3%), and against one epitope in two other donors (11Á1%). Due to the relatively low number of subjects in Cohort 1, we decided to include not only GLCTLVAML (EBV) and GILGFVFTL (influenza virus), but the six best performing MHC Dextramers for further analyses in Cohort 2.
Validation of the epitope panel
We screened the optimized six-epitope panel simultaneously as a pool of MHC Dextramers, on 44 biobank PBMC samples from human donors (Table 2 ) (Cohort 2). Ten were healthy, anonymous blood donors and 34 donor samples (19 men and 15 women) were obtained from a biobank established for the identification of M. tuberculosisreactive T cells. Of the 34 biobank donors, 17 were healthy but had positive IGRA (Tspot.TB, Oxford Immunotech) and therefore, by definition, had latent M. tuberculosis infection (LTBI); eight were M. tuberculosis-exposed but had shown no signs of M. tuberculosis infection (negative IGRA), eight were diagnosed with active TB, and one had documented previous TB (Table 2) . Median age was 45 years (interquartile range 38-56 years).
Of the 44 donors, one donor sample (no. 38) was excluded as CD3 and CD8 staining failed due to technical issues. Of the remaining 43 donor samples, 42 (97Á7%) responded positively to the six-epitope panel (Table 2 ). In 37 (86Á0%) cases, the positive response constituted > 50 absolute MHC-Dextramer-positive events; in five cases, the positive response constituted 11-49 absolute events. The last donor sample showed a low-frequency response consisting of 10 events (0Á073% of CD3 + CD8 + events), not satisfying our definition of a positive response. Flow cytometry plots showing Dextramer/PE versus Dextramer/APC positive events can be found in the Supplementary material (Fig. S1 ).
Factors influencing the magnitude of the response
There were no significant differences in the percentage of ASTC responding to the epitope panel between males and females or between different age groups (Fig. 2) . Healthy blood donors had significantly lower percentages of MHC-Dextramer-responding cells (geometric mean: 0Á36%), compared with healthy, M. tuberculosis-exposed donors (0Á90%), patients with LTBI (1Á18%) and patients with TB (0Á92%) (Fig. 2) . Routine laboratory whole blood lymphocyte counts could be obtained from patient records in 27 of the 34 patient samples in Cohort 2 (this data was not available for the 10 healthy blood donor samples). A single patient sample (no. 39) had a lymphocyte count below the lower limit of normal, at 0Á17 9 10 9 cells/l, but demonstrated a definite positive MHC-Dextramer response ( Table 2) .
Discussion
This study identified five epitopes from different viral antigens and a single melanoma-associated antigen, with broad coverage for detection of ASTC in healthy HLA A*0201-positive donors. The six-epitope panel was validated as a positive control for detection of ASTC in a cohort of healthy donors, patients with LTBI, and patients with a severe, chronic infectious disease (TB). By staining PBMC with all six epitopes in a pool, we demonstrated a good and robust coverage. Furthermore, the positive responses were strong and easily detectable, rendering the panel suitable as a positive control for studies in healthy controls as well as in infectious diseases. The panel yielded a coverage of 97Á7% for positive responses in the validation cohort.
The six epitopes included in the final panel were selected from initial screening of 21 candidate epitopes in 18 healthy blood donors. Though some epitopes showed high coverage in this population, great variations were seen in the frequency of positive responses between the 18 blood donors. Several factors could contribute to this variation. The exposure profile as well as the age of the blood donors could influence this pattern, as well as the HLA haplotypes of the donors; a dominant CTL response located to another, co-expressed HLA allele would not be detected by the HLA A*0201 MHC Dextramers used here. Additionally, the response seen here represents the immune status of the blood donors at the time of blood draw, and dynamic changes, for example during acute viral infections, can alter the responsiveness of CD8 + T cells as well as the composition of the CD8 + T-cell population, whereby a low-frequency memory CTL response would not reach our detection limit.
We found that the frequency of MHC-Dextramer-reactive ASTC was significantly lower among healthy blood donors than among the healthy controls, and the LTBI and TB patient groups. It can be argued that this might represent unspecific reactivity in the disease categories; on the other hand, we believe that unspecific MHC-Dextramer binding was to a large extent controlled for by including a nonsense-peptide-loaded MHC Dextramer, and by staining independently with MHC Dextramers loaded with two different fluorochromes. We were not able to retrieve information on age in the healthy blood donors; hence, we could not evaluate if the lower frequency of ASTC among the healthy blood donors Per cent of CTL 1 n/a n/a healthy 19Á9 184 represented an age effect. It should be noted that the PBMC from the blood donors were purified from buffy coats retrieved from a blood bank, whereas those from the IGRA-tested individuals were purified from fresh heparinized blood samples, and that purification was performed in two different laboratories. Although the purification protocols were harmonized, it cannot be ruled out that the preparation process has led to different reactivity and activation between the two categories. When studying ASTC in infectious diseases or when deciphering immune responses to malignant tumours, performance of laboratory analyses may be affected by altered immune responses due to treatment or disease. TB affects macrophage function, 20 and can also cause lymphopenia during severe infection, 21 though it is best described with regard to CD4 + T cells. However, as reactivity against the MHC Dextramer panel was preserved in patients with TB, we believe that it is in fact robust, probably also in other acute or chronic infections. Application on samples from severely ill patients with cancer will need prospective clinical evaluation, but we believe that robust performance is to be expected also in this patient group.
We included epitopes from major human viruses as well as a previously described melanoma epitope in the final panel. The epitope ELAGIGILTV is an analogue to the peptide Melan-A/MART-1 encoded by the gene MLANA, which is expressed in normal melanocytes as well as in most melanoma samples and cell lines. As the naturally occurring Melan-A [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (EAAGIGILTV) peptide binds poorly to HLA A*0201, Valmori et al. developed the analogue ELAGIGILTV by a single-amino acid substitution, 22 yielding stronger HLA A*0201 binding as well as a more efficient recognition by tumour-reactive T cells and melanoma-reactive cell lines. In addition to detection of ELAGIGILTV-reactive T cells in patients with melanoma, ELAGIGILTV-reactive CTL have also been described in many healthy donors, often exhibiting a memory phenotype. It has been suggested that this phenomenon may represent cross-reactivity, 23 although this is still not completely elucidated.
We tested three epitopes derived from measles virus, of which one (KLWESPQEI, C-protein 84-92 ) has been previously described to induce a CTL response during acute measles virus infection. 24 Amino acid substitutions have not been described in vaccine strains for any of the epitopes, 25 and therefore, they are most likely expressed in wild-type viral as well as in attenuated vaccine strains. None of the three epitopes yielded positive responses among the 18 donors in Cohort 1. Two possible explanations for this phenomenon should be considered. First, in the study describing a CTL response to one of the epitopes, 24 a response could only be detected during acute infection, but waned in the convalescent phase, suggesting that this specific epitope does not induce a long-term CTL response. Second, while a CTL response is detectable, at least during acute measles infection, long-term immunity after measles vaccination is predominantly humoral. 26 In Denmark, a publicly financed vaccination programme has included a live-attenuated measles vaccine (the measles-mumps-rubella vaccine) since 1987, 27 though some non-coordinated vaccination activity was seen already from the beginning of the 1980s. Though the blood donors included in Cohort 1 were anonymous, and we do not have access to information on whether they were born after the introduction of measles vaccination, it is possible that the absence of a CTL response is caused by protective immunity owing to vaccination rather than previous infection.
A single CMV epitope (NLVPMVATV) from the CMV antigen pp65 was included. This is known as a dominant HLA A*0201 restricted epitope upon CMV infection. MHC Dextramers with this epitope are suitable for monitoring CMV-specific CTL after bone marrow transplantation, 28 underlining its immunodominance. CMV is a 29 probably reflecting long-term low-level antigenic challenge during latent-phase infection. We did not observe an age effect on the magnitude of the ASTC detection, which may reflect that the age distribution in Cohort 2 was relatively uniform, or that the response to other included epitopes may be less age dependent, diluting a possible age affect in the response to the CMV epitope.
Regarding the two included influenza epitopes, abundant responses were seen towards GILGFVFTL, but not towards FMYSDFHFI. Both belong to a highly conserved antigenic target, and GILGFVFTL has previously been reported to yield higher-affinity responses in healthy donors. 30 Our data support that this is indeed a dominant influenza epitope.
Two EBV epitopes were included in the final panel; CLGGLLTMV from the latent-phase antigen LMP2 and GLCTLVAML from the lytic-phase antigen BMLF1, 31 the latter yielding the best coverage. The majority of adults worldwide have evidence of previous infection with the type-4 herpes virus EBV, as demonstrated by the presence of antibody responses, whereas only approx. 20% develop clinical mononucleosis upon primary infection. Virus-specific ASTC play a crucial role during acute EBV infection, when EBV-specific ASTC can comprise up to 10% of circulating CTL, 32 but the presence of EBV-specific ASTC is also important for lifelong control of EBV-related disease. 33 Three previously described HPV-derived epitopes (YMLDLQPETT, LLMGTLGIVC 34 and TIHDIILECV 35 ) were included in the screening phase, but later abandoned as we could only detect ASTC against one epitope in a single donor. These three epitopes were all derived from the HPV 16 protein E6. A previous study reported substantial promiscuity with regard to CTL reactivity against this peptide, which may explain the lack of response against these epitopes in Cohort 1.
Herpes simplex virus also infects the majority of the population at some stage of life and is capable of establishing latent infections. We included the epitopes RMLGDVMAV, YLANGGFLI and GIFEDRAPV from the HSV-1 glycoprotein B 36 and the HSV-2 epitope FLWEDQTLL, 37 whereof only one epitope yielded a response in one patient. With regard to the epitope ILIE-GIFFV from the varicella zoster virus protein ribonucleotide reductase subunit 2, ASTC responding to this epitope has also been shown to respond to homologous epitopes from HSV-1, HSV-2 and EBV. 38 Therefore, detection of responses towards this epitope may reside in theory from previous infection with any of these herpes viruses.
The most frequent responses to viral epitopes were seen against EBV, influenza and CMV epitopes. This corresponds to previous findings that a pool of 23 epitopes from these three viruses has a coverage of approximately 90% of individuals across Caucasian populations, by measuring interferon-ỵ production after simulation with a pool of peptides from cytomegalovirus, EBV and influenza virus (the CEF pool), 39 and it underscores the immunogenicity and widespread exposure to these viruses, at least in Caucasian populations. Further experiments comparing the epitope panel described here with T-cell stimulation assays like the CEF pool could help to elucidate the functional properties of the response seen in our study. However, as our aim was to establish a positive control assay for MHC multimer-based detection of ASTC, which do not depend on T-cell stimulation, such a comparison was beyond the scope of this study.
As expected, coverage of the initial panel varied substantially between donors. However, a coverage of 17/18 (94Á4%) donors was achieved using EBV(GLCTLVAML)-and influenza(GILGFVFTL) specific MHC Dextramers. To increase robustness in groups other than healthy blood donors, we included the six best performing epitopes in the final panel. The final six-epitope panel was chosen from evaluation of the initial results, while keeping in mind that covering dominant epitopes from a large number of different pathogens or endogenous targets will most likely increase robustness in larger and more heterogeneous population groups.
The current study has some limitations. We included only a single allele, HLA-A*0201, and only a limited number of healthy donor and TB patient samples. Among the Caucasian population, HLA-A*0201 is found in up to 50% of the population; 40 hence, including further alleles, and choosing matching epitopes would increase the overall usability of such a control assay. Also, including broader patient populations, such as patients with cancer and HIV-infected patients would provide important information on performance of the panel in these populations. We included patients with LTBI and TB as a model for different stages of chronic infections, and results from these populations may not be fully applicable to others with chronic or acute diseases affecting the cellular immune response. We did, however, find a strong positive response in a single patient with TB and low lymphocyte count, indicating that a CTL response to the chosen panel can be preserved, at least during moderate lymphocyte suppression.
In conclusion, we tested 21 epitopes derived from widespread viruses and two endogenous targets, previously shown to be immunogenic in HLA A*0201 subjects by flow cytometric analysis of MHC Dextramer-stained PBMC. Two of the epitopes alone yielded a coverage of 17/18 (94Á4%) in a cohort of 18 healthy blood donors. Subsequently, we selected a panel using the six epitopes yielding the highest coverage. We confirmed the applicability of this panel as a positive control for detection of antigen-specific CTL in HLA A*0201-positive patients, with a coverage of 97Á7% among a cohort of 43 patients constituting healthy blood donors, TB-exposed persons with or without LTBI, and patients with confirmed TB.
